23andMe Board Resigns Amid CEO's Controversial Buyout Plan

All seven independent directors stepped down after rejecting Anne Wojcicki's proposal to take the company private.

The board members cited a lack of a fully financed, actionable proposal as the primary reason for their resignation.
CEO Anne Wojcicki expressed surprise and disappointment at the mass resignation but remains committed to taking 23andMe private.
Since its 2021 IPO, 23andMe's stock has plummeted more than 95%, with recent valuations below $200 million.
The company has faced numerous challenges including declining DNA test sales, the end of a major research collaboration, and a significant data breach.
Wojcicki is now urgently seeking new independent directors who support her vision to take the company private.